

IN THE CLAIMS

Please amend the claims as follows:

Claims 1- 10 (Cancelled).

Claim 11 (Withdrawn; Currently Amended): A method for the treatment of psoriasis and inflammatory processes of the skin and/or joints of mammals and humans comprising:

administering to a patient in need thereof a composition ~~comprising an effective dose of a substance of the porphyrin synthesis, esters, acids, or pharmacologically compatible salt thereof according to claim 23~~; and

irradiating with light having a wavelength of 400 to 700 nm.

Claims 12-13 (Canceled).

Claim 14 (Withdrawn; Previously Presented): The method of Claim 11, wherein the substance of the porphyrin synthesis is 5-aminolevulinic acid or esters, or pharmacologically compatible salts thereof.

Claim 15 (Withdrawn; Currently Amended): The method of Claim [[12]] 11, wherein the salicylate is at least one selected from the group consisting of acetylsalicylic acid, salicylic acid, sodium salicylate, methyl salicylate and hydroxyethyl salicylate.

Claim 16 (Withdrawn; Previously Presented): The method of Claim 15, wherein the salicylate is acetylsalicylic acid.

Claim 17 (Withdrawn; Currently Amended): The method of Claim [[13]] 11, wherein the antioxidant is at least one selected from the group consisting of ascorbic acid, isoascorbic acid, tocopherol, gluconic acid, a carotenoid and a pharmacologically compatible salt of any of these.

Claim 18 (Withdrawn; Previously Presented): The method of Claim 17, wherein the antioxidant is ascorbic acid.

Claim 19 (Withdrawn; Previously Presented): The method of Claim 11, wherein the light has a wavelength of 520 to 580 nm.

Claim 20 (Withdrawn; Previously Presented): The method of Claim 19, wherein the light has a wavelength of approximately 545 nm.

Claim 21 (Withdrawn; Previously Presented): The method of Claim 11, wherein the psoriasis and inflammatory processes of the skin and/or joints of mammals and humans comprise at least one selected from the group consisting of arthritis, plaque psoriasis, arthritic psoriasis and neuropathy.

Claim 22 (Withdrawn; Previously Presented): The method of Claim 21, wherein the neuropathy is carpal tunnel syndrome or Bekterevev's disease.

Claim 23 (Currently Amended): A pharmaceutical composition comprising (i) a at least one substance of the porphyrin synthesis, esters, acids, or pharmacologically compatible salts thereof ~~in combination with a; (ii) at least one salicylate; and (iii) at least one~~

antioxidant, wherein the pharmaceutical composition is for the phototherapy of at least one condition selected from psoriasis and inflammatory processes of the skin and/or joints of mammals and humans.

Claim 24 (Previously Presented): The pharmaceutical composition of Claim 23, wherein the substance of porphyrin synthesis is 5-aminolevulinic acid, or esters or salts thereof.

Claim 25 (Previously Presented): The pharmaceutical composition of Claim 23, wherein the salicylate is at least one selected from the group consisting of acetylsalicylic acid, salicylic acid, sodium salicylate, methyl salicylate and hydroxyethyl salicylate.

Claim 26 (Previously Presented): The pharmaceutical composition of Claim 25, wherein the salicylate is acetylsalicylic acid.

Claim 27 (Canceled).

Claim 28 (Currently Amended): The pharmaceutical composition of Claim [[27]] 23, wherein the at least one antioxidant is at least one selected from the group consisting of ascorbic acid, isoascorbic acid, tocopherol, gluconic acid, a carotenoid and a pharmacologically compatible salt of any of these.

Claim 29 (Previously Presented): The pharmaceutical composition of Claim 28, wherein the antioxidant is ascorbic acid or a pharmacologically compatible salt thereof.

Claim 30 (Currently Amended): A pharmaceutical composition comprising:  
5-aminolevulinic acid;  
acetylsalicylic acid; and  
ascorbic acid; wherein  
the acetylsalicylic acid is in a weight ratio of 3:1 relative to the 5-aminolevulinic acid  
and the ascorbic acid is in a weight ratio of 2:1 relative to the 5-aminolevulinic acid; and the  
pharmaceutical composition is for the phototherapy of at least one condition selected from  
psoriasis and inflammatory processes of the skin and/or joints of mammals and humans.

Claim 31 (New): The pharmaceutical composition according to claim 23, wherein the  
composition is for treatment of arthritis.

Claim 32 (New): The pharmaceutical composition according to claim 30, wherein the  
composition is for treatment of arthritis.

Claim 33 (New; Withdrawn): The method of claim 11, wherein the method is for  
treatment of arthritis.